The Medical Advisor

By Dr. Frank Yap, MD  · One Day Media Network · Updated October 2026 · Data current to this date Quick Answer "GLP-1 2.0" is the second wave of obesity medicines built on semaglutide and tirzepatide. It improves on the first wave in five ways: more potency (retatrutide, a triple agonist, averaged 28.3% weight loss at 80 weeks in Lilly's TRIUMPH-1 trial), new mechanisms (amylin and glucagon), easier formats (daily pills already approved; monthly injections in Phase 3), better body composition , and lower prices . As of September 29, 2026, no next-generation injectable is approved yet : retatrutide's FDA filing is planned for Q1 2027 and CagriSema's FDA decision is expected in late 2026. Approved 2.0-era products today are the oral drugs (Wegovy pill, Foundayo) and high-dose Wegovy HD. Disclosure: This article is educational and is...

For over a decade and a half, the medical community has grappled with a paradox in cardiovascular health management: statins, the widely prescribed cholesterol-lowering drugs, while undeniably effective in lowering cholesterol, do little to reduce heart disease risk and cause significant side effects, including an increased risk of Type 2 diabetes.    In 2017, the Annals of Internal Medicine published an article titled "Statin Denial: An Internet-Driven Cult With Deadly Consequences." The article concluded : "What can thoughtful physicians do to counter these dangerous cults? We must work together to educate the public and enlist media support, and we must take the time to explain to our patients that discontinuing statin treatment may be a life-threatening mistake. Passive acceptance of harmful pseudoscience is not an option."! How do you distinguish truth from falsehood? If you find the recommendations of various professional groups confusing and prefer a well-ro...

Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: September 2026 Quick Answer Berberine, psyllium husk, and curcumin have the best human clinical evidence among natural Ozempic alternatives, though their weight-loss effect is modest (roughly 1–4 kg over 2–6 months) compared with semaglutide's 15%+ body-weight reduction. Berberine works through glucose and lipid metabolism, not by activating GLP-1 receptors the way Ozempic does — so "nature's Ozempic" is a catchy label, not a mechanistic match. As of September 2026, prescription GLP-1 drugs have also gotten dramatically cheaper (Wegovy from $349/month, Zepbound from $299/month via manufacturer cash-pay programs) and now come in oral pill form, which changes the cost-based case for natural alternatives even as safety and sustainability concerns remain valid reasons to consider them. There are natural alternatives to Ozempic like berberine, curcumin, and psyllium husk. ...